ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1916

KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model

Marta Del Rio Oliva1, Michael Basler1, Darrin Bomba2, Diana Lam2, Jennifer Brandl2, Christopher Kirk2 and Marcus Groettrup1, 1University of Konstanz, Konstanz, Germany, 2Kezar Life Sciences, Inc, San Francisco, CA

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, dermatomyositis, Mouse Models, Other, Muscle strength, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Polymyositis (PM) is a chronic autoimmune inflammatory myopathy affecting striated muscles and resulting in muscle weakness. PM is a rare disease, and there are limited approved therapies available. High-dose corticosteroids or IV immunoglobulin are commonly used to treat PM, however response is poor and both treatments contribute to comorbidity. Here we have investigated KZR-616, a first-in-class selective inhibitor of the immunoproteasome in C protein-induced myositis (CIM), a mouse model of PM that closely resembles the human disease. Positive results from this study support the rationale for PRESIDIO (KZR-616-003, NCT: NCT04033926), an ongoing Phase 2 clinical trial of KZR-616 in patients with PM and dermatomyositis (DM).

Methods: CIM was induced in female C57BL/6 mice (5/treatment group) immunized subcutaneously (SC) with 200 µg of fragment 2 (amino acids 284-580) of recombinant skeletal muscle fast-type C protein in complete Freund’s adjuvant combined with intraperitoneal (IP) administration of 2 µg of pertussis toxin. Diseased mice (Day 13 post immunization) were treated with 10 mg/kg KZR-616 or ONX 0914 (a structural analog of KZR-616) or vehicle three times per week until Day 28. Endpoints included muscle strength assessed by a grip strength meter, serum creatine kinase activity and immunohistology and immunohistochemistry of the triceps brachii muscle.

Results: Treatment with KZR-616 or ONX 0914 completely blocked the loss of grip strength in mice after vaccination for CIM induction while vehicle treated animals displayed progressive muscle weakness.  Compared to vehicle, immunoproteasome inhibition resulted in lowered PM-associated leukocyte infiltration of the triceps brachii muscle, including CD8+ T-cells and F4-80+ macrophages, and prevented an increase in serum creatine kinase.

Conclusion: Selective immunoproteasome inhibition shows therapeutic efficacy in a preclinical mouse model of PM with suppression of muscle inflammation and prevention of muscle weakness. These results strengthen the hypothesis that KZR-616, currently under evaluation in PRESIDIO (KZR-616-003, NCT: NCT04033926), a Phase 2 placebo-controlled, cross-over study of KZR-616 for patients with PM and DM evaluating safety, tolerability, and exploratory efficacy such as muscle function and disease activity over a 32 week treatment period, will elicit similar results.


Disclosure: M. Del Rio Oliva, None; M. Basler, None; D. Bomba, Kezar Life Sciences, 1, 3; D. Lam, Kezar Life Sciences, Inc, 1, 3; J. Brandl, Kezar Life Sciences, 1, 3; C. Kirk, Kezar Life Sciences, 1, 3, 4, 6, Kezar Life Sciences, 1, 3, 4, 6; M. Groettrup, Kezar Life Sciences, 2.

To cite this abstract in AMA style:

Del Rio Oliva M, Basler M, Bomba D, Lam D, Brandl J, Kirk C, Groettrup M. KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/kzr-616-a-first-in-class-selective-inhibitor-of-the-immunoproteasome-ameliorates-polymyositis-in-a-murine-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kzr-616-a-first-in-class-selective-inhibitor-of-the-immunoproteasome-ameliorates-polymyositis-in-a-murine-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology